UK-based Scancell has reported completion of its Phase I/II clinical trial of SCIB1 with positive results while treating patients with Stage III/IV malignant melanoma.

SCIB1 is the company's first cancer vaccine, which is plasmid DNA designed to encode human antibody molecule engineered to express two cytotoxic T-cell epitopes derived from the melanoma antigens Tyrosinase-Related Protein 2 (TRP2) and gp100 plus two helper T-cell epitopes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Results of the study suggested safe and tolerable administration of SCIB1 over a dose range of 0.4mg to 8mg.

Patients without tumours experienced stronger immune responses than patients with a detectable tumour, which thereby establishes efficacy of SCIB1 as a monotherapy to treat early stage patients with a small tumour.

"We are pleased that the clinical study report on our SCIB1 Phase I/II clinical trial in patients with melanoma has now been finalised, and will be able to support our US IND submission."

At a dose level of 8mg, SCIB1 was observed to have triggered strong immune response in the patients.

See Also:

Scancell CEO Dr Richard Goodfellow said: “We are pleased that the clinical study report on our SCIB1 Phase I/II clinical trial in patients with melanoma has now been finalised, and will be able to support our US IND submission.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are very encouraged by the compelling survival data generated in this study, which now demonstrates a median observation time since trial entry of more than four years for the 16 patients with resected tumours and receiving 2mg / 4mg doses of drug.

“This is supported by our long-term immune analysis that suggests continued dosing of SCIB1 may control disease in resected patients.”

The company is planning to file an investigational new drug (IND) application for SCIB1 in the first half of this year.